THERAPY DOSSIER · th-f9bb3f1d8a49

Tetrabromobenzotriazole (TBBt), with emodin as a second CK2 alpha inhibitor

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00801268 ↗NAterminated

AGENT-level surrogate (emodin comparator only): Tripterygium wilfordii with emodin in autosomal dominant polycystic kidney disease

Polycystic Kidney

Enrolment: 300 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26423352 ↗2015Reported benefit

The protein kinase 2 inhibitor tetrabromobenzotriazole protects against renal ischemia reperfusion injury.

MouseIschaemia-reperfusionRenalC57BL/6MaleIntraperitoneal injectionTBBt 1 or 2 mg/kg body weight in 200 microlitres of 5% DMSO…Pretreatment before ischaemia

Model: Bilateral renal pedicle clamping for 25 min followed by reperfusion

Ischaemia-reperfusion raised blood urea nitrogen and creatinine to 198.0 plus or minus 25.7 mg/dl and 2.4 plus or minus 0.7 mg/dl respectively. Pretreatment with 2 mg/kg TBBt significantly attenuated this, giving 135.4 plus or minus 19.4 mg/dl and 1.4 plus or minus 0.4 mg/dl (P less than 0.01), and…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…